World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
45664
World Ranking
8795
National Ranking
4532

Xavier Leleu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Xavier Leleu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 829 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Xavier Leleu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Xavier Leleu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Xavier Leleu is affiliated with Harvard University in the United States and has a significant presence in medical research, particularly focused on hematology and oncology. Their work extensively covers multiple myeloma, including its treatments and underlying biological mechanisms.

The main fields of study for Leleu include Medicine and Biochemistry, Genetics and Molecular Biology. Within these, their subfields of expertise are Hematology, Molecular Biology, Oncology, Genetics, and Pathology and Forensic Medicine.

Leleu's research topics prominently feature:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Cancer Mechanisms and Therapy

The scientist has contributed to several high-impact recent papers, including:

  • "Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma" (2023, New England Journal of Medicine)
  • "Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study" (2020, The Lancet)
  • "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" (2023, New England Journal of Medicine)
  • "Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial" (2021, The Lancet)
  • "Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial" (2021, The Lancet Oncology)

Leleu has frequent collaborative relationships with multiple researchers, including:

  • Philippe Moreau
  • Aurore Perrot
  • Meletios Α. Dimopoulos
  • Thierry Façon
  • Cyrille Touzeau

The scientist's work has been published extensively in notable medical journals and venues, with frequent contributions to:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • HemaSphere
  • Blood Cancer Journal

Leleu's extensive publication record includes over 700 works, primarily in medicine with strong emphasis on hematology and multiple myeloma research. Their research pursuits continue advancing understanding in cancer biology, immunotherapy approaches such as CAR-T cell therapy, and pharmacological strategies targeting hematologic malignancies.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot

  • Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Michel Attal;Valerie Lauwers-Cances;Cyrille Hulin;Xavier Leleu

  • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

    Philippe Moreau;Halyna Pylypenko;Sebastian Grosicki;Ievgenii Karamanesht

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Michel Attal;Paul G. Richardson;S. Vincent Rajkumar;Jesus San-Miguel

  • Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

    Brian A. Walker;Eileen M. Boyle;Christopher P. Wardell;Alex Murison

  • Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

    Yazan Alsayed;Hai Ngo;Judith Runnels;Xavier Leleu

  • Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

    Hervé Avet-Loiseau;Xavier Leleu;Murielle Roussel;Philippe Moreau

  • High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

    Arnaud Jaccard;Philippe Moreau;Véronique Leblond;Xavier Leleu

  • Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study

    Jean-Luc Harousseau;Michel Attal;Xavier Leleu;Jacques Troncy

  • Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

    Meletios A. Dimopoulos;Dominik Dytfeld;Sebastian Grosicki;Philippe Moreau

  • CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

    Abdel Kareem Azab;Judith M. Runnels;Costas Pitsillides;Anne-Sophie Moreau

  • Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

    Philippe Moreau;Thierry Facon;Xavier Leleu;Nadine Morineau

  • International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

    Evangelos Terpos;Gareth Morgan;Meletios Athanasios Dimopoulos;Matthew T. Drake

  • Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

    Thierry Facon;Hervé Avet-Loiseau;Gaëlle Guillerm;Philippe Moreau

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Leukemia (2012) 26 (149-157) DOI: 10.1038/leu.2011.196)

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

Frequent Co-Authors

Thierry Facon
Thierry Facon Centre Hospitalier Régional et Universitaire de Lille
Irene M. Ghobrial
Irene M. Ghobrial Harvard University
Philippe Moreau
Philippe Moreau University of Nantes
Denis Caillot
Denis Caillot Grenoble Alpes University
Steven P. Treon
Steven P. Treon Harvard University
Michel Attal
Michel Attal Janssen (Belgium)
Paul G. Richardson
Paul G. Richardson Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

In addition to a traditional medical degree, there are multiple online options for those seeking careers in healthcare. If you’re interested in healthcare leadership, consider one of the cheapest online mha programs. These programs provide essential management skills and open doors to administrative roles.

For nurses aiming to reach the highest level of practice, pursuing one of the cheapest dnp online programs can be a flexible and affordable way to earn a Doctor of Nursing Practice degree. DNP graduates often lead teams, influence healthcare policy, and improve patient outcomes.

Those interested in the pharmaceutical field may benefit from an online pharmacy degree. These degrees prepare you for diverse roles, from clinical pharmacy to research and education.

Technology-minded students can look into online schools for health information management. This field plays a critical role in healthcare data, compliance, and IT security.

Exploring these related online degrees can expand your career options and provide alternative pathways into the growing healthcare industry.

Best Scientists Citing Xavier Leleu

Trending Scientists

Recently Published Articles